In 2023, the average net patient revenue (NPR) for U.S. hospitals was 242.5 million U.S. dollars. Average NPR has increased yearly since 183.9 million U.S. dollars in 2018, except for in 2020. This drop in NPR could be explained by patients putting off non-urgent care during the COVID-19 pandemic.

According to a survey conducted in 2023,public hospitals belonging to Japan Red Cross, Social Welfare Organization Saiseikai, Welfare Federation of Agricultural Cooperatives Koseiren, and other associations generated an average annual revenue from medical practice of approximately *** billion Japanese yen in fiscal year 2022. In terms of revenue from nursing care, national hospitals topped with an average of roughly ** million yen.

According to a survey conducted in 2023, dental college hospitals generated an average annual revenue from medical practices of approximately *** billion Japanese yen in fiscal year 2022. When excluding public hospitals, private dental university hospitals recorded a revenue of around **** billion yen on average. Dental school hospitals in Japan usually consist of a main dentistry department and medical departments such as general internal medicine and ophthalmology departments.

Industry revenue fell by an average of 1.5% per year between 2020 and 2025. The inflation-related cost increases, which are not fully reflected in the prices that hospitals are allowed to charge the health insurance funds, are offset by legally capped revenue increases. The earnings situation has deteriorated for a large majority of hospitals following the coronavirus pandemic. In addition to a lack of inflation compensation, many hospitals have been affected by investment subsidies from the federal states that have been too low for years and various tariff increases.A tariff increase is also due in 2025, which is unlikely to be fully refinanced by the state and will hardly be offset by reserves or efficiency improvements. The persistent underfunding of operating costs due to the current statutory regulations poses an existential threat to hospitals. Hospitals are using up their reserves and falling into debt. In addition to going out of business, many hospitals are reducing important care services for financial reasons and implementing cost-cutting programmes such as staff reductions, site or department closures and bed closures. However, a slight increase in turnover of 1.8% to 162.7 billion euros is expected for 2025 compared to the previous year.For the period from 2025 to 2030, IBISWorld expects average annual sales growth of 1.9%. Turnover is therefore expected to reach 178.7 billion euros in 2030. Important prerequisites for growth are climate-friendly restructuring, digitalisation and process optimisation of treatment procedures. There is particular growth potential in the increasing outpatientisation of hospitals, which will be a key part of the structural change in healthcare. Demographic change poses a major challenge. A large proportion of employees will retire in the coming years and the vacant positions are only likely to be partially filled. At the same time, an ageing population and advances in medicine with new diagnostic and treatment methods will lead to an increase in demand for healthcare services, while the number of facilities is likely to fall due to high cost pressure as well as mergers and acquisitions. Smaller hospital operators in particular are increasingly joining together to form alliances in order to remain competitive against large hospital groups.

According to a survey conducted in 2023, the average annual revenue from medical practice among general hospitals in Japan amounted to approximately *** billion Japanese yen in the fiscal year 2022. Inpatient care accounted for the highest share of the average revenue from medical services, at around **** billion yen.

In FY 2024, the annual gross patient revenue of U.S. hospitals ranged from *** billion dollars in Wyoming to over ***** billion dollars in California. This statistic shows the annual gross patient revenue of U.S. hospitals by state in FY 2024.

Graph and download economic data for Total Revenue for Home Health Care Services, All Establishments (REV6216AMSA) from Q1 2009 to Q2 2025 about healthcare, revenue, establishments, health, services, housing, and USA.

Key Health App StatisticsTop Health AppsHealth & Fitness App Market LandscapeHealth App RevenueHealth Revenue by AppHealth App UsageHealth App Market ShareHealth App DownloadsKeeping track of...

This dataset is the average of annual percentage increase of health care expenditure information by state of residence between 1991-2009. Total health spending includes all privately and publicly funded hospital care, physician services, nursing home care, and prescription drugs etc. by state of residence. This spending includes hospital spending and is the total net revenue that is calculated as gross charges less contractual adjustments, bad debts, and charity care.

In 2023, Medicare payments contributed to 15.5 percent of all hospital net revenue, while private/self/other payments accounted for almost 69.9 percent of hospital revenue. Medicaid charges made up the rest - 14.6 percent. The share of private/self/other payments has steadily increased.

Average annual costs of running the supply chain at the central medical stores department (2020 US$).

Average annual supply chain operation costs, by health care facilities level (2020 US$) (N = 26).

The Organisation for Economic Co-operation and Development (OECD) Health Statistics offers the most comprehensive source of comparable statistics on health and health systems across OECD countries. It is an essential tool for health researchers and policy advisors in governments, the private sector and the academic community, to carry out comparative analyses and draw lessons from international comparisons of diverse health care systems. Within UKDS.Stat the data are presented in the following databases:

Health status

This datasets presents internationally comparable statistics on morbidity and mortality with variables such as life expectancy, causes of mortality, maternal and infant mortality, potential years of life lost, perceived health status, infant health, dental health, communicable diseases, cancer, injuries, absence from work due to illness. The annual data begins in 2000.

Non-medical determinants of health

This dataset examines the non-medical determinants of health by comparing food, alcohol, tobacco consumption and body weight amongst countries. The data are expressed in different measures such as calories, grammes, kilo, gender, population. The data begins in 1960.

Healthcare resources

This dataset includes comparative tables analyzing various health care resources such as total health and social employment, physicians by age, gender, categories, midwives, nurses, caring personnel, personal care workers, dentists, pharmacists, physiotherapists, hospital employment, graduates, remuneration of health professionals, hospitals, hospital beds, medical technology with their respective subsets. The statistics are expressed in different units of measure such as number of persons, salaried, self-employed, per population. The annual data begins in 1960.

Healthcare utilisation

This dataset includes statistics comparing different countries’ level of health care utilisation in terms of prevention, immunisation, screening, diagnostics exams, consultations, in-patient utilisation, average length of stay, diagnostic categories, acute care, in-patient care, discharge rates, transplants, dialyses, ICD-9-CM. The data is comparable with respect to units of measures such as days, percentages, population, number per capita, procedures, and available beds.

Health Care Quality Indicators

This dataset includes comparative tables analyzing various health care quality indicators such as cancer care, care for acute exacerbation of chronic conditions, care for chronic conditions and care for mental disorders. The annual data begins in 1995.

Pharmaceutical market

This dataset focuses on the pharmaceutical market comparing countries in terms of pharmaceutical consumption, drugs, pharmaceutical sales, pharmaceutical market, revenues, statistics. The annual data begins in 1960.

Long-term care resources and utilisation

This dataset provides statistics comparing long-term care resources and utilisation by country in terms of workers, beds in nursing and residential care facilities and care recipients. In this table data is expressed in different measures such as gender, age and population. The annual data begins in 1960.

Health expenditure and financing

This dataset compares countries in terms of their current and total expenditures on health by comparing how they allocate their budget with respect to different health care functions while looking at different financing agents and providers. The data covers the years starting from 1960 extending until 2010. The countries covered are Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, and United States.

Social protection

This dataset introduces the different health care coverage systems such as the government/social health insurance and private health insurance. The statistics are expressed in percentage of the population covered or number of persons. The annual data begins in 1960.

Demographic references

This dataset provides statistics regarding general demographic references in terms of population, age structure, gender, but also in term of labour force. The annual data begins in 1960.

Economic references

This dataset presents main economic indicators such as GDP and Purchasing power parities (PPP) and compares countries in terms of those macroeconomic references as well as currency rates, average annual wages. The annual data begins in 1960.

These data were first provided by the UK Data Service in November 2014.

According to Cognitive Market Research, the global Sepsis Treatment Market size will be USD 4590 million in 2025. It will expand at a compound annual growth rate (CAGR) of 6.70% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 1698.30 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 1331.10 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 1101.60 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2033.
South America has a market share of more than 4% of the global revenue with a market size of USD 174.42 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 183.60 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2033.
Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 100.98 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2033.
Hospitals category is the fastest growing segment of the Sepsis Treatment Market

Market Dynamics of Sepsis Treatment Market

Key Drivers for Sepsis Treatment Market

Increasing prevalence of sepsis and hospital-acquired infections

Sepsis is a life-threatening condition caused by the body's extreme response to infection which is becoming more common due to factors such as an aging population, the rising incidence of chronic diseases, and the overuse of antibiotics leading to antimicrobial resistance. According to the World Health Organization (WHO), the average hospital-wide cost of sepsis was estimated to be more than US$ 32,000 per patient in high-income countries. Sepsis affects millions of people worldwide each year, with a significant proportion of cases resulting from HAIs. Moreover, the growing burden of HAIs, particularly in intensive care units (ICUs), further contributes to the expansion of the sepsis treatment market. Patients in ICUs are highly susceptible to infections due to prolonged hospital stays, the use of invasive medical devices such as catheters and ventilators, and weakened immune systems. Bacterial, fungal, and viral infections acquired in hospital settings often progress to severe sepsis or septic shock, necessitating prompt medical intervention. This has led to increased adoption of advanced therapies, including antimicrobial treatments, blood purification techniques, and supportive care strategies such as renal replacement therapy.

https://www.who.int/news-room/fact-sheets/detail/sepsisGrowing awareness and early diagnosis initiatives

Governments, healthcare organizations, and industry players are investing in awareness campaigns and diagnostic advancements. These efforts aim to educate healthcare professionals and the general public about the early signs of sepsis, enabling timely intervention and treatment. As a result, the demand for rapid diagnostic tools, biomarker-based tests, and advanced monitoring systems is increasing, boosting the overall market growth. Furthermore, countries have implemented national sepsis management programs that emphasize early detection and treatment protocols. For instance, initiatives like the Surviving Sepsis Campaign provide clinical guidelines and educational resources to improve sepsis recognition and response. In addition, advancements in artificial intelligence (AI) and machine learning are enhancing early sepsis detection through predictive analytics, reducing the burden on healthcare providers and improving patient outcomes. These technological advancements, combined with growing awareness efforts, are significantly contributing to the expansion of the sepsis treatment market.

Restraint Factor for the Sepsis Treatment Market

High cost of sepsis treatment and critical care management

Sepsis is a life-threatening condition that requires immediate medical intervention, often involving intensive care unit (ICU) admission, advanced diagnostic tests, organ support therapies, and prolonged hospital stays. These factors contribute to substantial healthcare expenses that makes sepsis treatm...

The range of services offered by specialist practices for certain illnesses, injuries or preventative measures is essential for healthcare and is benefiting from the ageing population and rising patient numbers. Sector revenues have risen by an average of 10.3% per year over the past five years. The capped budgeting of services and the cost increases in energy, rents and wages, which have not been adequately refinanced, have put increasing pressure on the earnings situation of industry players in recent years. Specialist practices in energy-intensive areas such as radiology or neurology have been particularly hard hit by rising energy prices.In addition to various cost increases, structural problems such as a worsening shortage of skilled labour and excessive bureaucracy are putting a strain on outpatient care structures. An increasing number of requirements, documentation obligations and checks are taking up time and increasingly restricting the time and localisation of patient care. There is a threat of long waiting times for specialist appointments, an ongoing freeze on the admission of new patients and further service cuts for patients in specialist practices. This development in turn puts a damper on revenue growth.The orientation value negotiated by the National Association of Statutory Health Insurance Physicians and the National Association of Statutory Health Insurance Funds for 2024 is to be increased by 3.85%, meaning that specialists will receive more money for the same amount of services. However, this increase is unlikely to fully cover the cost increases for rent, energy and practice requirements. In 2024, the salaries of medical assistants alone have risen by 7.4% across all pay scale groups.In 2025, turnover in the sector is expected to amount to 47.1 billion euros. This corresponds to a decline in turnover of 0.6% compared to the previous year. Rising operating expenses, cost increases due to innovations and the growing need for medical care due to an increasing number of patients are leading to a continuous rise in financial expenditure and putting pressure on the profitability of many practices. A further increase in remuneration rates is expected accordingly.IBISWorld expects industry turnover to increase at an average annual rate of 1.5% over the next five years and reach 50.6 billion euros in 2030. The increasing level of digitalisation and rising investment in new medical technology equipment should lead to more efficient practice processes. Against the backdrop of a shortage of skilled labour, however, the supply bottleneck is likely to worsen in the coming years and place an additional burden on the workforce. In all likelihood, waiting times for specialist appointments will continue to rise as a result and fewer new customers will be able to be accepted.

Global Healthcare Business Intelligence - BI market size 2025 was XX Million. Healthcare Business Intelligence - BI Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

The UK has an ageing population. For the Residential Nursing Care industry, this is an opportunity for growth, with demand for more beds expanding. Homes have upped their average weekly fees, contributing to revenue growth. Soaring inflation over the two years through 2023-24 has further raised nursing home fees. However, state involvement has limited growth, which has kept care fees artificially low for many nursing home residents. Residential nursing care revenue is anticipated to climb at a compound annual rate of 2.9% over the five years through 2025-26 to £10.3 billion, including a forecast hike of 1.2% in 2025-26. Weak government funding and wage cost pressures caused by the rising National Living Wage (which climbed to £12.21 in April 2025) have constrained profitability. Labour supply shortages caused by high turnover rates have been of particular concern. According to Skills For Care, the job vacancy rate in 2023-24 in the adult care sector was 8.3%, far above the average rate in the UK economy. That being said, the vacancy rate is declining, mainly thanks to a government-driven recruitment drive to attract overseas workers, which has been helped by reducing visa requirements. Climbing real household disposable income has supported more self-funded residents, aiding residential nursing care. However, data from the Office for National Statistics reveals the percentage of self-funded residents fell from 36.7% in 2019-20 to 34.9% over the year through February 2022. Families were struggling with the rising cost of living, reducing the number of people able to afford private care home costs, which constrained revenue growth. In the year through February 2023, the number of self-funded residents at nursing care homes climbed to 37% of the 372,035 residents. In the two years through 2025-26, interest rates have fallen, stimulating spending on discretionary services like residential nursing homes. Real disposable income is inching up in line with wage costs, which is raising demand for self-funded residents and lifting care homes’ revenue. Over the five years through 2030-31, residential nursing care revenue is estimated to expand at a compound annual rate of 2.3% to £11.5 billion. Robust demand from an ageing population will support industry growth. However, plans for adult social care reforms are to be released in two stages (the first in 2026 and the second in 2028), which has caused greater uncertainty for the sector's future. Staff shortage concerns will continue to plague nursing care.

According to a survey conducted in 2023, public hospitals belonging to prefectures and municipalities recorded a **** percent of loss in the fiscal year 2022, the lowest profit and loss ratio among general hospitals in Japan. Hospitals founded by private individuals, by comparison, recorded a profit of *** percent on a median value.

The number of hospitals in the United States was forecast to continuously decrease between 2024 and 2029 by in total 13 hospitals (-0.23 percent). According to this forecast, in 2029, the number of hospitals will have decreased for the twelfth consecutive year to 5,548 hospitals. Depicted is the number of hospitals in the country or region at hand. As the OECD states, the rules according to which an institution can be registered as a hospital vary across countries.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the number of hospitals in countries like Canada and Mexico.

According to Cognitive Market Research, the global Enoxaparin Sodium Injection market size was USD 4415.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1766.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1324.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1015.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 220.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 88.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.
The Prevents Intravenous Thrombosis section is rapidly expanding the Enoxaparin Sodium Injection industry

Market Dynamics of Enoxaparin Sodium Injection Market

Key Drivers for Enoxaparin Sodium Injection Market

Growing awareness of preventive healthcare measures

This increase in awareness of preventive healthcare measures drives the Enoxaparin Sodium Injection market. More people are enlightened about the benefit of preventing such thromboembolic events, and health care providers are increasingly recommending anticoagulant therapies as part of routine care, particularly for at-risk populations. Awareness has also given more importance to early intervention and management of conditions that could lead to complications such as deep vein thrombosis or pulmonary embolism. Add to this the campaigns of educational sources and the guidelines of health organizations encouraging the use of Enoxaparin in both hospital and outpatient sectors, which in turn enhances the increased adoption. This driver, therefore improves patients' outcomes while at the same time contributing to overall market growth. For instance, in 2022. Cipla created a campaign to raise awareness about asthma care and the benefits of preventive inhalers.

Restraint Factor for the Enoxaparin Sodium Injection Market

High cost of Enoxaparin compared to other anticoagulants

One of the key constraints in the market's growth is the relatively high cost of Enoxaparin compared to other anticoagulants. Most healthcare providers and patients experience budget constraints and are influenced by more affordable alternatives. This price differential would lower the prescription rate of Enoxaparin, especially in less developed regions with low healthcare budgets. Additionally, out-of-pocket and insurance cover fees for the patient might also affect the use of Enoxaparin relative to cheaper alternatives. This would mean that the financial burden associated with Enoxaparin may limit its access and uptake, thus impacting sales and growth in the market. Therefore, cost-related issues need to be addressed for the increased use of Enoxaparin in clinical practice.

Opportunity for the Enoxaparin Sodium Injection Market

Advancements in drug delivery systems

Advances in drug delivery systems are driving growth in the Enoxaparin Sodium Injection market. Progress on modes of delivery, including prefilled syringes and auto-injectors, help make Enoxaparin more convenient and easier to administer to both prescribers and patients. These developments ensure accurate dosing and, to a greater extent, avoid contamination, improving patient compliance as well as results. Secondly, the availability of user-friendly devices for the administration of this drug enable its self-administration, especially in out-patient clinics. The market shares are influenced more by the shift towards the management of diseases outside the hospital setting and onto delivery systems that are continually evolving, thereby allowing for full utilization of Enoxaparin, thus driving the growth of the market.

Impact of Covid-19 on the Enoxaparin Sodium Injection Market

The COVID-19 pandemic has been impactful on the Enoxaparin Sodium Injection market. Upstream, an associated incr...